SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature

E-ISSN： 1873-4286|23|10|1510-1521

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.23, Iss.10, 2017-05, pp. : 1510-1521

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cardiovascular risk and prevention in diabetes mellitus

By Roberts Aled W

Clinical Medicine, Vol. 10, Iss. 5, 2010-10 ,pp. : 495-499

Royal College Of Physicians

Access to resources Recommend Favorite

Pharmacological Strategies to Reduce Cardiovascular Risk in Type 2 Diabetes Mellitus: An Update

By Marcel M.C. Hovens Jouke T. Tamsma Edith D. Beishuizen Menno V. Huisman

Drugs, Vol. 65, Iss. 4, 2005-01 ,pp. : 433-445

Adis International

Access to resources Recommend Favorite

Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations

By Scheen André J

Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, Iss. 5, 2014-05 ,pp. : 647-663

Informa Healthcare

Access to resources Recommend Favorite

Cardiovascular risk scores improve prescribing in diabetes mellitus

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 398, 2003-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Management of Type 2 Diabetes Mellitus and Cardiovascular Risk: Lessons from Intervention Trials

By Yki-Järvinen H.

Drugs, Vol. 60, Iss. 5, 2000-11 ,pp. : 975-983

Adis International

Access to resources Recommend Favorite